Central nervous system infection with multi-drug-resistant gram-negative bacilli
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 79 years; 2. In line with the American Infectious Diseases Association (IDSA) diagnostic criteria for central nervous system infections-carbapenem-resistant gram-negative bacilli infections; 3. Due to clinical needs, it is necessary to receive combined antibiotic therapy based on polymyxin E sodium methanesulfonate; 4. Agree to participate in the trial and sign the relevant informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with severe liver and kidney dysfunction; 2. Patients with a history of allergies to colistin E sodium methanesulfonate or other combined use of antibacterial drugs and their excipients; 3. Female patients during pregnancy, lactation or perinatal period; 4. Dying patients with brain death and unstable vital signs; 5. The drugs that the patient is using and must use may seriously affect the efficacy of the trial drug or increase its adverse reactions; 6. The patient and (or) the legal representative sign the Do Not Rescue (DNR), or decide to withdraw the life support treatment (withdraw) or limit the life support treatment intensity (withhold) and sign the relevant informed consent; 7. The patient has participated in a clinical intervention trial in the past 3 months; 8. The patient is a researcher or his immediate family, etc., where there may be improper informed consent; 9. Patients who are considered unsuitable to participate in this trial by the attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cure rate of central nervous system infection; | — |
Countries
China
Contacts
Henan Provincial People's Hospital